In Celexir’s muscle–recovery category, TB4 (Thymosin Beta-4) is positioned for cardiovascular and musculoskeletal tissue repair, supporting whole-body recovery from inflammation and stress-induced damage. It’s used as an adjunct in orthopedic rehab, post-illness deconditioning, or cardiometabolic recovery programs—alongside sleep, load management, and anti-inflammatory care.
Mechanistically, TB4 activates progenitor cells, improves endothelial repair, and balances fibrotic vs. regenerative remodeling, mapping to faster granulation, re-epithelialization, and microvascular support in healing tissues. These pathways complement protocols aimed at restoring durability in tendons, muscle, and vascular beds.
Evidence for TB4’s biology is strong in preclinical models, with a growing translational interest in tissue repair; however, large, modern randomized human trials remain limited, so it should be framed as an investigational adjunct in performance or recovery plans with objective tracking (time-to-function, pain/function scores, exercise tolerance).
Celexir delivery & specs: typical catalog guidance 1–2 mg per dose (clinical judgment); >98% purity with GMP CoA/MSDS; 2–8 °C storage; lyophilized vial or prefilled pen options for clean, repeatable workflows from warehouse to administration.